Literature DB >> 15318095

Polymorphisms of interleukin-1 beta and beta 3-adrenergic receptor in Japanese patients with nonalcoholic steatohepatitis.

Yasuko Nozaki1, Toshiji Saibara, Yoshihisa Nemoto, Masafumi Ono, Naoaki Akisawa, Shinji Iwasaki, Yoshihiro Hayashi, Makoto Hiroi, Hideaki Enzan, Saburo Onishi.   

Abstract

BACKGROUND: Obesity, hypertriglyceridemia, and diabetes have been reported as frequent complications observed in patients with nonalcoholic steatohepatitis (NASH) in Western countries. The aim of this study was to investigate the genetic predisposition on NASH pathogenesis in the Japanese population.
METHODS: Genotypes of two previously described functional polymorphisms-beta3-adrenergic receptor 190 T/A polymorphism, which results in Trp64Arg (W64R) amino acid replacement, and interleukin-1beta-511 T/C polymorphism in the promoter sequence-were determined in 63 Japanese NASH patients and 100 healthy volunteers using polymerase chain reaction and restriction fragment length polymorphism.
RESULTS: beta3-adrenergic receptor R allele frequency and the R/- (W/R and R/R) genotype frequency were significantly higher in NASH patients than those in control subjects. Interleukin-1beta-511 T allele frequency and the T/T genotype frequency were significantly higher in NASH patients than those in control subjects. Obesity, hypertriglyceridemia, and hyperinsulinemia were associated with NASH patients with the R/- genotype, whereas an increase in fasting plasma glucose level and a decrease in insulinogenic index were associated with NASH patients with the W/W genotype.
CONCLUSION: This study confirmed the contribution of obesity, glucose intolerance, and hypertriglyceridemia to NASH development in the Japanese population. In addition to these factors, genetic predispositions to obesity and inflammation in the Japanese population were shown to contribute much to the development of NASH.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15318095     DOI: 10.1111/j.1530-0277.2004.tb03226.x

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  18 in total

1.  Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice.

Authors:  Kouichi Miura; Yuzo Kodama; Sayaka Inokuchi; Bernd Schnabl; Tomonori Aoyama; Hirohide Ohnishi; Jerrold M Olefsky; David A Brenner; Ekihiro Seki
Journal:  Gastroenterology       Date:  2010-03-27       Impact factor: 22.682

Review 2.  Genetic background in nonalcoholic fatty liver disease: A comprehensive review.

Authors:  Fabio Salvatore Macaluso; Marcello Maida; Salvatore Petta
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 3.  Genetic and epigenetic mechanisms of NASH.

Authors:  Mohammed Eslam; Jacob George
Journal:  Hepatol Int       Date:  2015-12-18       Impact factor: 6.047

4.  Association of IL-1β, IL-1Ra and FABP1 gene polymorphisms with the metabolic features of polycystic ovary syndrome.

Authors:  Nadia Rashid; Aruna Nigam; Pikee Saxena; S K Jain; Saima Wajid
Journal:  Inflamm Res       Date:  2017-04-12       Impact factor: 4.575

5.  Metabolically induced liver inflammation leads to NASH and differs from LPS- or IL-1β-induced chronic inflammation.

Authors:  Wen Liang; Jan H Lindeman; Aswin L Menke; Debby P Koonen; Martine Morrison; Louis M Havekes; Anita M van den Hoek; Robert Kleemann
Journal:  Lab Invest       Date:  2014-02-24       Impact factor: 5.662

Review 6.  Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Sanja Stojsavljević; Marija Gomerčić Palčić; Lucija Virović Jukić; Lea Smirčić Duvnjak; Marko Duvnjak
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

7.  Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms.

Authors:  J E Nelson; P Handa; B Aouizerat; L Wilson; L A Vemulakonda; M M Yeh; K V Kowdley
Journal:  Aliment Pharmacol Ther       Date:  2016-10-11       Impact factor: 8.171

8.  Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease.

Authors:  Tatsuki Ichikawa; Kazuhiko Nakao; Keisuke Hamasaki; Ryuji Furukawa; Shotarou Tsuruta; Yasuo Ueda; Naota Taura; Hidetaka Shibata; Masumi Fujimoto; Kan Toriyama; Katsumi Eguchi
Journal:  Hepatol Int       Date:  2007-06-01       Impact factor: 6.047

Review 9.  Clinical features of nonalcoholic steatohepatitis in Japan: Evidence from the literature.

Authors:  Masafumi Ono; Toshiji Saibara
Journal:  J Gastroenterol       Date:  2006-08       Impact factor: 7.527

10.  Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH).

Authors:  Masato Yoneda; Takashi Uchiyama; Shingo Kato; Hiroki Endo; Koji Fujita; Kyoko Yoneda; Hironori Mawatari; Hiroshi Iida; Hirokazu Takahashi; Hiroyuki Kirikoshi; Masahiko Inamori; Yuichi Nozaki; Noritoshi Kobayashi; Kensuke Kubota; Satoru Saito; Shiro Maeyama; Mina Sagara; Hiroyuki Aburatani; Tatsuhiko Kodama; Atsushi Nakajima
Journal:  BMC Gastroenterol       Date:  2008-11-14       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.